Fairness Definitions and Metrics in Deep Reinforcement Learning for Drug Discovery in Healthcare: A Rapid Evidence Review

• URL: http://arxiv.org/abs/2606.02902v1
• Date: Mon, 01 Jun 2026 21:18:27 GMT
• Title: Fairness Definitions and Metrics in Deep Reinforcement Learning for Drug Discovery in Healthcare: A Rapid Evidence Review
• Abstract summary: There is no concise synthesis of how fairness is defined, measured, and tested in DRL-based drug discovery.<n>We focus on three questions: (i) how dataset composition and split strategies, especially scaffold versus random splits, affect evaluation and distribution shift; (ii) how reward design (e.g., QED, docking, toxicity, synthetic accessibility) can create or mitigate bias, with emphasis on cancer targets; and (iii) which measurable metrics best capture fairness.
• Score: 2.198430261120653
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Deep reinforcement learning (DRL) is increasingly applied to de novo molecular design, but choices in data, rewards, and evaluation can yield uneven performance across disease areas and chemotypes. Despite this, there is no concise synthesis of how fairness is defined, measured, and tested in DRL-based drug discovery. In this rapid evidence review, we synthesize fairness definitions and metrics for DRL-driven molecule generation in healthcare. We focus on three questions: (i) how dataset composition and split strategies, especially scaffold versus random splits, affect evaluation and distribution shift; (ii) how reward design (e.g., QED, docking, toxicity, synthetic accessibility) can create or mitigate bias, with emphasis on cancer targets; and (iii) which measurable metrics best capture fairness. This includes parity across cancer versus non-cancer indications and across cancer subtypes. It also includes distributional balance in key physicochemical descriptors, scaffold/chemotype diversity, groupwise validity, toxicity, and synthetic accessibility. From 2017 onward, we searched major biomedical, computer science, and engineering literature databases and used arXiv for horizon scanning. Records were screened using PRISMA-style procedures and analyzed via content coding to link reported parity outcomes to dataset and reward choices. Our review provides a concise set of fairness definitions and metrics for DRL molecule generation. It offers practical guidance for reporting distribution parity and outcome parity. It also summarizes how dataset and reward choices relate to observed parity effects and identifies open gaps relevant to trustworthy, cancer-relevant DRL generation.

Related papers

• Eliciting Medical Reasoning with Knowledge-enhanced Data Synthesis: A Semi-Supervised Reinforcement Learning Approach [62.0906177191353]
  Existing approaches distill chain-of-thought reasoning traces from large proprietary models via supervised fine-tuning, then conduct reinforcement learning (RL)<n>We propose MedSSR, a Medical Knowledge-enhanced data Synthesis and Semi-supervised Reinforcement learning framework.<n>Our framework first employs rare disease knowledge to synthesize distribution-controllable reasoning questions.<n>We then utilize the policy model itself to generate high-quality pseudo-labels. This enables a two-stage, intrinsic-to-extrinsic training paradigm: self-supervised RL on the pseudo-labeled data, followed by supervised RL on the human-annotated real data
  arXiv  Detail & Related papers  (2026-04-13T14:37:38Z)
• MedConclusion: A Benchmark for Biomedical Conclusion Generation from Structured Abstracts [6.305549902494417]
  MedConclusion is a large-scale dataset of structured abstracts for biomedical conclusion generation.<n>Each instance pairs the non-conclusion sections of an abstract with the original author-written conclusion.<n>MedConclusion also includes journal-level metadata such as biomedical category and SJR.
  arXiv  Detail & Related papers  (2026-04-07T22:34:02Z)
• An Interpretable Machine Learning Framework for Non-Small Cell Lung Cancer Drug Response Analysis [3.416642353308202]
  In personalized medicine, treatments are tailored according to the individual's genetic information along with lifestyle aspects.<n>This paper focuses on the development of personalized treatment plans using specific patient data focusing on the genetic profile.<n>Multi-Omics data from Genomics of Drug Sensitivity in Cancer have been used to build a predictive model.<n>XGBoostor is utilized to predict the drug response focusing on molecular and cellular features extracted from cancer datasets.
  arXiv  Detail & Related papers  (2026-03-17T10:01:26Z)
• Exploring Drug Safety Through Knowledge Graphs: Protein Kinase Inhibitors as a Case Study [3.487220175067471]
  Adverse Drug Reactions (ADRs) are a leading cause of morbidity and mortality.<n> Existing prediction methods rely mainly on chemical similarity, machine learning on structured databases, or isolated target profiles.<n>We present a knowledge graph-based framework that unifies diverse sources, drug-target data (EMBL), clinical trial literature (ChBL), trial metadata (ClinicalTrials.gov), and post-marketing safety reports (FAERS)<n>The resulting network enables contextual comparison of efficacy, phenotypic and target similarity, and ADR prediction via target-to-adverse-event correlations.
  arXiv  Detail & Related papers  (2026-02-17T12:30:33Z)
• Adapting HFMCA to Graph Data: Self-Supervised Learning for Generalizable fMRI Representations [57.054499278843856]
  Functional magnetic resonance imaging (fMRI) analysis faces significant challenges due to limited dataset sizes and domain variability between studies.<n>Traditional self-supervised learning methods inspired by computer vision often rely on positive and negative sample pairs.<n>We propose adapting a recently developed Hierarchical Functional Maximal Correlation Algorithm (HFMCA) to graph-structured fMRI data.
  arXiv  Detail & Related papers  (2025-10-05T12:35:01Z)
• Causal Representation Learning from Multimodal Biomedical Observations [57.00712157758845]
  We develop flexible identification conditions for multimodal data and principled methods to facilitate the understanding of biomedical datasets.<n>Key theoretical contribution is the structural sparsity of causal connections between modalities.<n>Results on a real-world human phenotype dataset are consistent with established biomedical research.
  arXiv  Detail & Related papers  (2024-11-10T16:40:27Z)
• Regressor-free Molecule Generation to Support Drug Response Prediction [83.25894107956735]
  Conditional generation based on the target IC50 score can obtain a more effective sampling space. Regressor-free guidance combines a diffusion model's score estimation with a regression controller model's gradient based on number labels.
  arXiv  Detail & Related papers  (2024-05-23T13:22:17Z)
• Bt-GAN: Generating Fair Synthetic Healthdata via Bias-transforming Generative Adversarial Networks [3.3903891679981593]
  We present Bias-transforming Generative Adversarial Networks (Bt-GAN), a GAN-based synthetic data generator specifically designed for the healthcare domain. Our results demonstrate that Bt-GAN achieves SOTA accuracy while significantly improving fairness and minimizing bias.
  arXiv  Detail & Related papers  (2024-04-21T12:16:38Z)
• Unsupervised EHR-based Phenotyping via Matrix and Tensor Decompositions [0.6875312133832078]
  We provide a comprehensive review of low-rank approximation-based approaches for computational phenotyping. Recent developments have adapted low-rank data approximation methods by incorporating different constraints and regularizations that facilitate interpretability further.
  arXiv  Detail & Related papers  (2022-09-01T09:47:27Z)
• Bootstrapping Your Own Positive Sample: Contrastive Learning With Electronic Health Record Data [62.29031007761901]
  This paper proposes a novel contrastive regularized clinical classification model. We introduce two unique positive sampling strategies specifically tailored for EHR data. Our framework yields highly competitive experimental results in predicting the mortality risk on real-world COVID-19 EHR data.
  arXiv  Detail & Related papers  (2021-04-07T06:02:04Z)
• A Systematic Approach to Featurization for Cancer Drug Sensitivity Predictions with Deep Learning [49.86828302591469]
  We train >35,000 neural network models, sweeping over common featurization techniques. We found the RNA-seq to be highly redundant and informative even with subsets larger than 128 features.
  arXiv  Detail & Related papers  (2020-04-30T20:42:17Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.